{"id":3863,"date":"2023-02-07T17:53:00","date_gmt":"2023-02-07T16:53:00","guid":{"rendered":"https:\/\/saccosystem.com\/single-news\/sacco-system-launches-microbiome\/"},"modified":"2024-12-09T19:18:16","modified_gmt":"2024-12-09T18:18:16","slug":"sacco-system-launches-microbiome","status":"publish","type":"news","link":"https:\/\/saccosystem.com\/en\/news\/sacco-system-launches-microbiome\/","title":{"rendered":"Sacco System Launches Microbiome"},"content":{"rendered":"\n
\n
\n

Sacco System Launches Microbiome \u2013 The complete suite of products and services tailored for the development and scale-up of Probiotics, Postbiotics and Microbial Therapeutics for supplement, biotech and pharma companies.<\/em><\/p>\n\n\n\n

The FDA defines live biotherapeutics (LBPs) as biological products that contains live organisms and are applied to the prevention, treatment, or cure of a disease or condition. Interest in LBPs as a solution to several health disorders has grown exponentially in the last few years. In full support of this vision, Sacco System is launching Microbiome by Sacco System<\/a><\/strong>: its full suite of active ingredients and services conceived for the development and scale-up of Probiotics, Postbiotics and (LBPs)Microbial Therapeutics for application to the supplement, biotech, and pharma industries.<\/p>\n\n\n\n

Microbiome blooms in the fertile environment of Sacco System\u2019s proud tradition of continuous innovation and evolution to meet our global customers\u2019 changing needs. The launch of the new Microbiome market area will provide fundamental support to our clients in the development of innovative solutions, while concurrently offering them a substantial sale and marketing edge with respect to their competitors. <\/p>\n\n\n\n

\u201cWe have been working with Biotherapeutics for many years: CSL Centro Sperimentale del Latte<\/strong> has been among the first producers of probiotics to boast a facility qualified for the manufacturing of microbial pharmaceutical ingredients. Today, we have two production sites hosting a whole range of different processes and fermentations, as well as the downstream capacity ensuing from holding a Drug GMP certification.With the launch of our new Microbial Therapeutic business-line we are directing our efforts and strong focus to the field of Biotherapeutics. Thanks to the excellent skills and competencies of the people who have joined us, marrying into our existing capabilities, we are fully equipped to offer a complete suite of excellent services to our partners, with a view of bringing next-gen bacteria-based therapeutics to the market\u201d \u2013 Marco Caspani<\/strong>, Executive Director of the Microbiome Division of Sacco System. <\/p>\n\n\n\n

Sacco System Australia<\/strong> has been recently founded to support our customers\u2019 live biotherapeutics development needs and allows us to take advantage of the outstanding scientific know-how present there.<\/p>\n\n\n\n

\u201cWe are very proud to be bringing forward a 150-year-old legacy with the expansion of Sacco System\u2019s operating facilities, focusing on Microbial Therapeutics, into the Australian market. This expansion marks an exciting next step for the Live Biotherapeutics industry given the array of opportunities opened by Sacco\u2019s capabilities, from small to large scale Pharma development, its multinational reach and its research capabilities. As CEO for the Sacco System Australia business, the team and I look forward to providing high-quality, tailor-made solutions for the process development, fermentation in the Microbial Therapeutic Bio-Pharma industry.\u201d \u2013 John Goebel<\/strong>, CEO of Sacco System Australia. <\/p>\n\n\n\n

\u201cSacco System have decided to leverage their expertise in all aspects of microbiology to enter the Biotherapeutics market. This new investment by Sacco System will provide a unique offering of leading-edge manufacturing and support for companies looking to outsource their biotherapeutics products. Boasting an Australia-based development facility built according to Quality by Design and seamlessly integrated into the fully automated GMP production facilities in Italy, that is supported by state-of-the-art analytics, Sacco System can now bring your project from the bench through to 20,000L batches in GMP. Our team\u2019s expertise, ranging from growing strains -from aerobes to strict anaerobes- to flow cytometry and large-scale manufacturing, is at your disposal to ensure the success of your drug substance development and commercial production.\u201d \u2013 Max Rossetto<\/strong>, Global Business Development Director for Microbial Therapeutics of Sacco System. <\/p>\n\n\n\n

Sacco System is proudly launching its new Microbiome<\/strong> market area to support companies worldwide in the development, process validation, and commercial production of probiotics, postbiotics, Next-Generation bacteria<\/em> (from aerobic to obligate anaerobic strains) and live biotherapeutics (LBPs).<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n

<\/p>\n

\n
\n
\n

\n Latest News <\/h2>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n
\n
\n
\n
\n 19 March 2026 <\/div>\n
\n <\/div>\n <\/div>\n
\n
\n A regulatory achievement for Sacco System: our Heat-Inactivated CRL1505\u00ae receives GRAS status <\/div>\n
\n <\/div>\n
\n

An important regulatory goal has been achieved with the conclusion reached by an independent expert panel for the self-affirmed GRAS (Generally Recognized as Safe) determination of our postbiotic CRL1505\u00ae HI.<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 24 January 2026 <\/div>\n
\n <\/div>\n <\/div>\n
\n
\n SYNBIO\u00ae: Sacco System’s probiotic support for healthy ageing <\/div>\n
\n <\/div>\n
\n

The global population is ageing faster than ever before. In 2019, life expectancy at birth reached 72.8 years almost 9 years more than in 1990. In this context, staying healthy<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 22 December 2025 <\/div>\n
\n <\/div>\n <\/div>\n
\n
\n Sacco System grows in Latin America: BioInsumos in Uruguay and Sacco Brasil acquired. <\/div>\n
\n <\/div>\n
\n

The Group is accelerating its South American growth strategy through a twofold transaction: the acquisition of a Uruguayan company and the full absorption of its Brazilian subsidiary. The Group is<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 11 December 2025 <\/div>\n
\n <\/div>\n <\/div>\n
\n
\n Sacco System Presents\u00a0PerforMilk\u00ae: Unlocking Milk\u2019s Full Potential by Preserving Protein Quality\u00a0 <\/div>\n
\n <\/div>\n
\n

Milk is the most precious resource in dairy production. High-quality dairy products start with high-quality milk\u2014and in today\u2019s rapidly evolving dairy landscape, protecting that quality has never been more critical. <\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 20 November 2025 <\/div>\n
\n <\/div>\n <\/div>\n
\n
\n Unveiling the survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME\u00ae model <\/div>\n
\n <\/div>\n
\n

\u201cSurvivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME\u00ae model\u201d is the title of the study that has been<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 07 February 2025 <\/div>\n
\n <\/div>\n <\/div>\n
\n
\n L. rhamnosus CA15 Achieves GRAS Status: A Milestone for Women’s Health <\/div>\n
\n <\/div>\n
\n

GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 08 January 2025 <\/div>\n
\n <\/div>\n <\/div>\n
\n
\n Sacco System Australia\u2019s Heat-Inactivated Postbiotics Receive Positive Recommendations from FSANZ <\/div>\n
\n <\/div>\n
\n

Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 25 November 2024 <\/div>\n
\n News <\/div>\n <\/div>\n
\n
\n Our 2023 sustainability report is online! <\/div>\n
\n <\/div>\n
\n

We are proud to present the fifth edition of our Sustainability Report, an opportunity to reflect on the milestones achieved and the challenges ahead…<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 16 April 2024 <\/div>\n
\n News <\/div>\n <\/div>\n
\n
\n Sacco System is pleased to announce the grand opening of its development site in Australia. <\/div>\n
\n <\/div>\n
\n

Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland…<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 26 March 2024 <\/div>\n
\n News <\/div>\n <\/div>\n
\n
\n Sacco System companies have been awarded as Sustainability champions by Ecovadis <\/div>\n
\n <\/div>\n
\n

At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici…<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 18 March 2024 <\/div>\n
\n News <\/div>\n <\/div>\n
\n
\n List Biotherapeutics and Sacco System Announce Lead Share Agreement <\/div>\n
\n <\/div>\n
\n

List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement…<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n 26 February 2024 <\/div>\n
\n News <\/div>\n <\/div>\n
\n
\n CSL FRANCE becomes SACCO SYSTEM FRANCE <\/div>\n
\n <\/div>\n
\n

Sacco System is the international biotechnological company dedicated to the food, nutraceutical, and pharmaceutical industries…<\/p>\n <\/div>\n <\/div>\n

\n
\n \n Read Article <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
<\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Sacco System Launches Microbiome \u2013 The complete suite of products and services tailored for the development and scale-up of Probiotics…<\/p>\n","protected":false},"featured_media":2062,"template":"","meta":{"_acf_changed":false},"category_news":[345],"tag_news":[],"class_list":["post-3863","news","type-news","status-publish","has-post-thumbnail","hentry","category_news-news-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/saccosystem.com\/en\/wp-json\/wp\/v2\/news\/3863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saccosystem.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/saccosystem.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/saccosystem.com\/en\/wp-json\/wp\/v2\/media\/2062"}],"wp:attachment":[{"href":"https:\/\/saccosystem.com\/en\/wp-json\/wp\/v2\/media?parent=3863"}],"wp:term":[{"taxonomy":"category_news","embeddable":true,"href":"https:\/\/saccosystem.com\/en\/wp-json\/wp\/v2\/category_news?post=3863"},{"taxonomy":"tag_news","embeddable":true,"href":"https:\/\/saccosystem.com\/en\/wp-json\/wp\/v2\/tag_news?post=3863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}